Intra-Cellular Therapies stock rocketed Tuesday after its drug, Caplyta, topped expectations in a depression treatment study.

Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ...

In the assessment of 12-month price targets, analysts unveil insights for Intra-Cellular Therapies, presenting an average ...

Intra-Cellular's commercial momentum remains strong, with strong sequential and YoY growth in the first quarter. Find out ...

NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and ...

NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ...

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) just reported positive results from one of its phase 3 studies using lumateperone as an adjunctive therapy to antidepressants for the treatment of ...

Intra-Cellular Therapies now has data showing its drug met key goals of a pivotal clinical trial, beating a placebo in this indication. The results build the case for expanding the product’s ...

Intra-Cellular says efficacy results, favorable safety profile, convenient dosing, make Caplyta compelling treatment option for depression. Topline results from the second Phase 3 study ...

Discover the groundbreaking patent by Intra-Cellular Therapies Inc for stable amorphous solid dispersions of ITI-007 tosylate salt. Learn about the innovative methods, compositions, and potential ...